Article Details
Retrieved on: 2024-03-14 20:16:07
Tags for this article:
Click the tags to see associated articles and topics
Summary
The FDA has approved Rezdiffra, the first drug for MASH—a form of liver disease linked to metabolic syndrome and conditions like fibrosis—developed by biopharma company Madrigal Pharmaceuticals. The approval offers new hope for managing liver diseases, including those exacerbated by factors such as alcohol and obesity.
Article found on: www.biopharmadive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here